期刊
CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 16, 期 2, 页码 -出版社
SPRINGER
DOI: 10.1007/s11864-014-0324-2
关键词
Prostate cancer; Chemotherapy; Metastatic; Docetaxel; Cabazitaxel; Mitoxantrone
类别
资金
- Sanofi-Aventis
- Medivation/Astellas
- Janssen
- Dendreon
Prostate cancer (PC) is the most common cancer in men in the United States. Although outcomes are excellent for early-stage disease, survival for men with metastatic PC is limited. While older studies did not supported the use of chemotherapy in PC, the efficacy of taxane chemotherapy plus prednisone is now well established in men with metastatic castration resistant PC (CRPC). The results of CHAARTED trial have further expanded the use of chemotherapy to patients with metastatic hormone-sensitive disease. The clinical efficacy of taxanes over other chemotherapeutics may be a result of its ability to inhibit microtubule-dependent trafficking of proteins such as the androgen-receptor (AR). Ongoing research uses chemotherapy earlier in the disease course as well as explores the utility of combining cytotoxic chemotherapy with biologic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据